Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Employees

Sector

Biotechnology & Medical Research

More about the company

07-30	US officials pressed China on rare earths, farm goods commitments, Bessent says	RE
07-29	Bioxytran Announces Publication of Corporate Research Report Discussing Prolectin-M Phase 2 Results, Planned 408-Patient Registrational Trial, Bxt-25 Oxygen-Therapeutic Platform, and A-Suqar Commercial Distribution Agreement	CI

Market Cap	2.5M 2.17M 2.02M 1.86M 3.5M 239M 3.57M 23.88M 9.35M 119M 9.39M 9.18M 399M	P/E 2024	-5.27x	P/E 2025	-3.28x
Enterprise Value	3.24M 2.82M 2.61M 2.41M 4.54M 309M 4.62M 30.95M 12.12M 154M 12.17M 11.9M 517M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.38%	Yield 2024 *	-	Yield 2025	-

07-30	US officials pressed China on rare earths, farm goods commitments, Bessent says	RE
07-29	Bioxytran Announces Publication of Corporate Research Report Discussing Prolectin-M Phase 2 Results, Planned 408-Patient Registrational Trial, Bxt-25 Oxygen-Therapeutic Platform, and A-Suqar Commercial Distribution Agreement	CI
07-16	Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst	RE
05-15	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt	CI
03-18	Bioxytran, Inc. announced that it has received $1.158942 million in funding	CI
03-04	Bioxytran Inc Announces Positive Dose Optimization Results And Advances Toward Phase 3 Registrational Trial For ProLectin-M	CI
03-02	Bioxytran Inc reports positive phase 1b/2a clinical study results for Prolectin-M, broad-range antiviral drug in mild to moderate Covid-19	RE
02-17	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical Ltd for A-SUQAR Dietary Supplement	CI
02-11	Bioxytran reports positive phase 2 results demonstrating rapid viral clearance with Prolectin-Mbioxytran	RE
02-11	Bioxytran, Inc. Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with Prolectin-Mbioxytran	CI
02-03	Bioxytran, Inc. and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics	CI

07-29	Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research	AQ
05-29	Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25	AQ
03-20	BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT	AQ
03-04	Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M	AQ
02-23	Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus	AQ

Manager	Title	Age	Since
David Platt CEO	Chief Executive Officer	73	01/09/2018
Ola Soderquist DFI	Director of Finance/CFO	65	01/09/2018
Leslie Ajayi CTO	Chief Tech/Sci/R&D Officer	-	-

US Rare Earth Minerals Inc Stock Other OTC

Stocks

US9034101082

Biotechnology & Medical Research

Valuation: US Rare Earth Minerals Inc

Latest news : US Rare Earth Minerals Inc

Press Releases: US Rare Earth Minerals Inc

Managers and Directors: US Rare Earth Minerals Inc

Bio Therapeutic Drugs

Financials

Company Profile

Director	Title	Age	Since
Dale Conaway BRD	Director/Board Member	71	02/11/2018
Alan Hoberman BRD	Director/Board Member	73	02/11/2018
David Platt CHM	Chairman	73	01/09/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-0.81%	-0.33%	+27.15%	+81.12%	55.23B
ARGENX SE	-3.74%	-6.32%	+42.70%	+64.45%	53.75B
BIONTECH SE	-0.11%	+0.86%	-15.63%	-13.56%	23.48B
INSMED INCORPORATED	-1.58%	-5.51%	-3.51%	+375.36%	22B
WUXI BIOLOGICS (CAYMAN) INC.	+2.65%	-0.82%	+20.43%	-12.06%	19.78B
GENMAB A/S	-1.23%	-3.15%	+26.00%	-31.88%	17.44B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.87%	-5.64%	+16.59%	+541.96%	14.66B
EXELIXIS, INC.	+1.16%	+0.58%	+51.87%	+181.96%	14.07B
PHARMAESSENTIA CORPORATION	-5.09%	-10.87%	+153.11%	+272.20%	13.02B
Average	-0.89%	-1.55%	+35.41%	+162.17%	25.94B
Weighted average by Cap.	-1.25%	-0.44%	+30.73%	+124.82%

	2024	2025
Net sales	-	-
Net income	-2.37M -2.06M -1.91M -1.76M -3.32M -226M -3.38M -22.6M -8.85M -112M -8.89M -8.69M -377M	-2.12M -1.84M -1.71M -1.58M -2.97M -203M -3.03M -20.27M -7.94M -101M -7.97M -7.8M -339M
Net Debt	1.09M 946K 878K 810K 1.53M 104M 1.55M 10.4M 4.07M 51.63M 4.09M 4M 174M	741K 643K 597K 551K 1.04M 70.72M 1.06M 7.07M 2.77M 35.12M 2.78M 2.72M 118M

End-of-day quote Other OTC Other stock markets
- ^USD	-